Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
About this trial
This is an interventional treatment trial for Multiple Myeloma and Plasma Cell Neoplasm focused on measuring primary systemic amyloidosis
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of primary systemic (AL) amyloidosis within the past 12 months High- or low-risk disease, determined by the extent of systemic organ involvement with disease and patient age PATIENT CHARACTERISTICS: Age 18 and over Performance status SWOG 0-3 Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Cardiovascular No New York Heart Association class III or IV congestive heart failure No restrictive cardiomyopathy requiring oxygen No myocardial infarction within the past 6 months No symptomatic cardiac arrhythmia within the past 60 days Other No other active malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I cancer in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy for AL amyloidosis Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other No other prior or concurrent therapy for AL amyloidosis
Sites / Locations
- Memorial Sloan-Kettering Cancer Center